Table 1.
JPH203 Radioligand Binding Screening Results
| Target | % inhibition | % stimulation | Species |
|---|---|---|---|
| Adenosine A1 | 37 | Human | |
| Adenosine A2A | 15 | Human | |
| α2A adrenergic | 2 | Human | |
| β1 adrenergic | 10 | Human | |
| β2 adrenergic | 2 | Human | |
| α1A adrenergic | 3 | Rat | |
| α1B adrenergic | 3 | Rat | |
| L-type Ca channel | 2 | Human | |
| Cannabinoid CB1 | 5 | Human | |
| Dopamine D1 | 9 | Human | |
| Dopamine D25 | 8 | Human | |
| GABAA flunitrazepam | 35 | Rat | |
| GABAA muscimol | 1 | Rat | |
| NMDA | 3 | Rat | |
| Histamine H1 | 18 | Human | |
| Imidazoline I2 | 13 | Rat | |
| Opiate, μ | 6 | Human | |
| Phorbol ester | 3 | Mouse | |
| Potassium channel [KATP] | 11 | Human | |
| Potassium channel hERG | 3 | Human | |
| Prostanoid EP4 | 6 | Human | |
| Rolipram | 27 | Rat | |
| Serotonin (5-HT2B) | 1 | Human | |
| Sigma | 19 | Human | |
| Sodium channel, site 2 | 25 | Rat | |
| Norepinephrine transporter | 20 | Human |